Co-Authors
This is a "connection" page, showing publications co-authored by S CHEENU KAPPADATH and ARMEEN MAHVASH.
Connection Strength
4.715
-
Quantitative evaluation of 90Y-PET/CT and 90Y-SPECT/CT-based dosimetry following Yttrium-90 radioembolization. Med Phys. 2024 Sep; 51(9):6061-6074.
Score: 0.961
-
A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study. BMC Gastroenterol. 2022 Mar 28; 22(1):151.
Score: 0.827
-
Hepatocellular Carcinoma Tumor Dose Response After 90Y-radioembolization With Glass Microspheres Using 90Y-SPECT/CT-Based Voxel Dosimetry. Int J Radiat Oncol Biol Phys. 2018 10 01; 102(2):451-461.
Score: 0.635
-
A comparison of methods for in vivo activity and absorbed dose quantification with PET/CT following yttrium-90 radioembolization. Med Phys. 2024 Sep; 51(9):6034-6045.
Score: 0.240
-
Predicting the net administered activity in 90 Y-radioembolization patients from post-procedure 90 Y-SPECT/CT. Med Phys. 2023 Nov; 50(11):7003-7015.
Score: 0.225
-
Factors modulating 99m Tc-MAA planar lung dosimetry for 90 Y radioembolization. J Appl Clin Med Phys. 2022 Dec; 23(12):e13734.
Score: 0.212
-
Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol. 2021 Dec 21; 27(47):8166-8181.
Score: 0.203
-
A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1129-1145.
Score: 0.199
-
Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma. 2020; 7:117-131.
Score: 0.186
-
Planning dosimetry for 90 Y radioembolization with glass microspheres: Evaluating the fidelity of 99m Tc-MAA and partition model predictions. Med Phys. 2020 Oct; 47(10):5333-5342.
Score: 0.186
-
Blood flow diversion using the microvascular plug to avoid non target delivery of radioactive microspheres. Radiol Case Rep. 2020 Oct; 15(10):2015-2017.
Score: 0.185
-
Calculation of lung mean dose and quantification of error for 90 Y-microsphere radioembolization using 99m Tc-MAA SPECT/CT and diagnostic chest CT. Med Phys. 2019 Sep; 46(9):3929-3940.
Score: 0.170
-
Selective Internal Radiation Therapy With Yttrium-90 Glass Microspheres: Biases and Uncertainties in Absorbed Dose Calculations Between Clinical Dosimetry Models. Int J Radiat Oncol Biol Phys. 2016 11 15; 96(4):888-896.
Score: 0.140
-
Comparing voxel-based absorbed dosimetry methods in tumors, liver, lung, and at the liver-lung interface for (90)Y microsphere selective internal radiation therapy. EJNMMI Phys. 2015 Dec; 2(1):16.
Score: 0.130
-
International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021 05; 48(5):1570-1584.
Score: 0.048
-
Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. J Vasc Interv Radiol. 2020 Jul; 31(7):1035-1043.e2.
Score: 0.046
-
Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy. Cardiovasc Intervent Radiol. 2020 Feb; 43(2):246-253.
Score: 0.044
-
Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity. Cardiovasc Intervent Radiol. 2019 Mar; 42(3):413-425.
Score: 0.041
-
Adequate SIRT activity dose is as important as adequate chemotherapy dose. Lancet Oncol. 2017 11; 18(11):e636.
Score: 0.038